A gallstone-related drug, already approved in Asia and Europe, could enter human clinical trials soon as an experimental way to block Type 1 diabetes before patients even develop symptoms.
In a paper published Monday in the Journal of Clinical Investigation, researchers at Stanford University and Seattle’s Benaroya Research Institute at Virginia Mason Hospital said a study of the drug — called hymecromone — blocked production of a substance that is essential for the development of Type 1 diabetes. Although the study was in mice, they believe the drug ultimately could be used to stop a disease that afflicts one in 300 people in the United States.
Hey, check out all the research scientist jobs. Post your resume today!
